Professor James Arnold Academics Supervisors Professor and Head of Tumour Immunology Group Research subject areas Cancer Contact details james.n.arnold@kcl.ac.uk +44 (0) 20 7848 6415
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment CD47 Knock-Out Using CRISPR-Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo CO and cancer An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma Perivascular tumor-associated macrophages and their role in cancer progression LYVE-1 + macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development Antibody conjugates for targeted delivery of toll-like receptor 9 agonist to the tumor tissue Predicting Progression Free Survival after Systemic Therapy in Advanced Head and Neck Cancer: Bayesian regression and Model development Redox-triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt(IV)-Prodrug Chemoimmunotherapy Approach The effects of radiation therapy on the macrophage response in cancer Immune cell-antibody interactions in health and disease Tinker, Tailor, Soldier, Cell; The Role of C-Type Lectins in the Defense and Promotion of Disease Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression Lyve-1 expressing macrophages direct the expansion of pericytes within the perivascular niche to support angiogenesis in cancer. Macrophages orchestrate the expansion of a pro-angiogenic perivascular niche during cancer progression Generation of hypoxia-sensing chimeric antigen receptor T cells Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors The Diverse Roles of Heme Oxygenase-1 in Tumor Progression ImmunoCluster provides a computational framework for the non-specialist to profile high- dimensional cytometry data Cytotoxic chemotherapy as an immune stimulus: A molecular perspective on turning up the immunological heat on cancer Repurposing tin mesoporphyrin as a novel immune checkpoint therapy in the treatment of cancer: A preclinical evaluation. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α A chemical approach to immunoprotein engineering: chemoselective functionalization of thioester proteins in their native state Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation Novel glycan biomarkers for the detection of lung cancer View all publications
11 August 2025 New cancer drug boosts effectiveness of chemotherapy – even in resistant tumours A groundbreaking cancer drug could enhance how patients respond to chemotherapy even in…